 CAMBRIDGE, Mass.--BUSINESS WIRE--Seres Therapeutics, Inc. Nasdaq: MCRB, a leading microbiome therapeutics company, announced the presentation of its final 24-week data from the pivotal Phase 3 ECOSPOR III study evaluating SER-109, an investigational oral microbiome therapy for recurrent C. difficile infection rCDI. The data presented today in a poster of distinction at Digestive Disease Week 2021 demonstrated that SER-109 significantly reduced recurrence rates compared to placebo over 24 